

CXCR1 and CXCR2 haplotypes synergistically modulate cystic fibrosis lung disease

Michael S.D. Kormann^{1*}, Andreas Hector¹, Veronica Marcos², Lauren E. Mays¹, Matthias Kappler², Thomas Illig³, Norman Klopp³, Sonja Zeilinger³, Melanie Carevic¹, Nikolaus Rieber¹, Olaf Eickmeier⁴, Stefan Zielen⁴, Amit Gaggar⁵, Barbara Moepps⁶, Matthias Griesse² and Dominik Hartl¹

¹ Children's Hospital and Interdisciplinary Center for Infectious Diseases, University of Tübingen, Tübingen, Germany

² Emmy-Noether Group, Research Center, University Children's Hospital, Munich, Germany

³ Institute of Epidemiology, Helmholtz Zentrum, Neuherberg, Germany

⁴ Department of Pediatric Pulmonology, Allergy and Cystic Fibrosis, Children's Hospital, Frankfurt, Germany

⁵ Department of Medicine, University of Alabama at Birmingham, Birmingham, Alabama, USA

⁶ Institute of Pharmacology and Toxicology, University of Ulm Medical Center, Ulm, Germany

* Corresponding author: Michael Kormann, Wilhelmstr. 31, 72074 Tübingen, Germany, michael.kormann@me.com; Tel. +49 7071 2984305

FUNDING/SUPPORT

Supported by the German Research Foundation (DFG, Emmy Noether Programme HA 5274/3-1 to D.H.), the German Society of Pediatric Pneumology (D.H.), PINA e.V. (D.H.) and the Novartis Foundation (D.H.).

RUNNING HEAD

CXCR1/2 modulates CF lung disease

ABSTRACT

Cystic fibrosis (CF) lung disease severity is largely independent of the CF transmembrane conductance regulator (CFTR) genotype, indicating the contribution of genetic modifiers. The chemokine receptors CXCR1 and CXCR2 have been found to play essential roles in the pathogenesis of CF lung disease. Here, we determine whether genetic variation of *CXCR1* and *CXCR2* influences CF lung disease severity.

Genomic DNA of CF patients in Germany (n=442) was analyzed for common variations in *CXCR1* and *CXCR2* using a single-nucleotide polymorphism (SNP) tagging approach. Associations of *CXCR1* and *CXCR2* SNPs and haplotypes with CF lung disease severity, CXCR1 and CXCR2 expression, and neutrophil effector functions were assessed.

Four SNPs in *CXCR1* and three in *CXCR2* strongly correlated with age-adjusted lung function in CF patients. SNPs comprising haplotypes *CXCR1*_Ha and *CXCR2*_Ha were in high linkage disequilibrium and patients heterozygous for the *CXCR1*-2 haplotype cluster (*CXCR1*-2_Ha) had lower lung function compared to patients with homozygous wild-type alleles ($FEV_1 \leq 70$: OR = 7.24; $P = 2.30 \times 10^{-5}$). CF patients carrying *CXCR1*-2_Ha showed decreased CXCR1 combined with increased CXCR2 mRNA and protein expression and displayed disturbed antibacterial effector functions.

CXCR1 and *CXCR2* genotypes modulate lung function and antibacterial host defense in CF lung disease.

200 words

Key words: cystic fibrosis, polymorphism, chemokines, lung function, G-protein coupled receptor

INTRODUCTION

Chronic lung disease determines the morbidity and mortality of cystic fibrosis (CF) patients [1]. CF lung disease is characterized by a detrimental feed-back loop of bacterial infection and perpetuated inflammation. Although the underlying mechanisms are still poorly understood, previous studies provided evidence that neutrophils represent the key effector cells in this disease condition. CF airway fluids contain millions of activated neutrophils, but these professional phagocytes are inefficient in their antibacterial functionality [2]. Neutrophils are recruited and activated by the chemokine CXCL8 through its two cognate seven transmembrane G-protein coupled receptors (GPCR) CXCR1 (IL-8RA) and CXCR2 (IL-8RB), which are both highly expressed on the neutrophil surface. CXCR1 has been identified as a critical component in the pathogenesis of CF lung disease, as CXCR1 mediates antibacterial host defense in CF airways [2]. High CXCR1 surface expression levels were associated with preserved lung function of CF patients and vice versa.

Disease severity in CF patients is largely independent of the *CFTR* genotype, indicating the contribution of genetic modifiers [3]. Several genetic modifiers have already been reported in CF patients, including Transforming *Growth Factor beta 1* (*TGFbeta1*), *IFRD1*, *MBL2* and a recently reported locus on chromosomes 11p13 and 20q13.2 [4-8]. Based on the functional importance of CXCR1 and CXCR2 in neutrophilic inflammation, and the documented contribution of genetic modifiers to the severity of CF lung disease, we hypothesized that genetic variants regulate CXCR1 and CXCR2 expression levels in CF patients and may have critical impact on CF lung disease severity.

METHODS

Patients

Informed written consent was obtained from all subjects included in the study, their parents or their legal guardians, and all study methods were approved by the local ethics and by the institutional review board. Only subjects who regularly visited our CF care unit, at least once every 6 months over the course of the last 5 years, were included in our studies. In total, 442 CF patients were included in this study. Details of the CF patient population are given in Supplementary Table 1. The CF group included 224 male and 218 female patients with a mean age of 21.4 ± 12.6 (SD) years. Inclusion criteria were the diagnosis of CF by clinical symptoms and positive sweat tests or disease-inducing mutations, forced expiratory volume in 1 second (FEV_1) > 25 % of predicted value and being on stable concomitant therapy at least 2 weeks prior to the study. For 28 patients, no FEV_1 data at the time of blood drawing was available and therefore those patients were not included in the FEV_1 association analyses. Longitudinal FEV_1 values, calculated from a minimum of five consecutive years of CF patient data, were available for 318 CF patients and were utilized to calculate the FEV_1 predicted at age of 20 years, as previously reported by Schluchter et al. [9]. In total, we have included 13,256 FEV_1 values into our longitudinal analyses. To compare *CXCR1/2* SNPs between CF and healthy control populations we included 395 healthy subjects from the KORA population [10]. KORA (Cooperative Health Research in the Region Augsburg) is a regional research platform for population-based surveys and subsequent follow-up studies in the fields of epidemiology, health economics, and health care research [10]. The KORA F4 study is a follow-up of the KORA S4 study, a population-based health survey conducted in the city of Augsburg and two surrounding counties between 1999 and 2001.

Quantitative RT-PCR

Expression levels were quantified in duplicate by real-time quantitative RT-PCR with the use of SYBR green and the iCycler iQ detection system (Biorad, Hercules, CA, USA). Cycle threshold (Ct) values for genes of interest were normalized to β -actin and used to calculate the relative quantity of mRNA expression. For primer sequences see Supplementary Table 2.

***CXCR1/CXCR2* genotyping**

Polymorphisms with a minor allele frequency > 1% were selected based on the mutation screening performed by Vasilescu *et al.* [11] and genotyped in above described CF population to investigate the influence of SNPs on CF lung disease. Genomic DNA was extracted from whole blood by a standard salting out method and DNA samples were genotyped using matrix-assisted laser desorption/ionization time-of-flight (MALDI-TOF) mass spectrometry (Sequenom, San Diego, CA, USA) as described in detail elsewhere [12]. PCR assays and associated extension reactions were designed using the SpectroDESIGNER software (Sequenom). Specific primer sequences are given in Supplementary Table 2.

Neutrophil isolation

Neutrophils from peripheral blood were isolated by Ficoll gradient centrifugation. After isolation, neutrophils were washed in PBS, counted and resuspended in RPMI 1640 or HBSS. The purity of the neutrophil suspensions was > 93%, as determined by May-Grünwald-Giemsa staining and staining Ficoll-isolated neutrophil fractions with CD11b and CD16 antibodies using flow cytometry as recently described [13, 14]. Note: peripheral blood was processed immediately after drawing from a single CF center, thereby excluding transportation or center-to-center variation.

FACS analysis

CXCR1/2 surface staining was performed as previously described [2]. Briefly, freshly obtained neutrophils from peripheral blood underwent Fc blocking and were then incubated

with the respective monoclonal antibodies for 40 min, washed three times and analyzed by flow cytometry (FACSCalibur, Becton-Dickinson, Heidelberg, Germany). Calibrator beads were used to adjust the FACS instrument settings and normalize the data. 10,000 neutrophils were analyzed per sample. CXCR1 and CXCR2 were stained on neutrophils using antibodies from BD Biosciences (San Diego, USA). CXCR1 and CXCR2 antibodies from the same clone were used for all stainings performed, and antibody concentrations were normalized to neutrophil numbers, correcting for differences in neutrophil counts among different CF patients. Isotype controls set to a fixed threshold were subtracted from the respective specific antibody expression and the results were reported as mean fluorescence intensity (MFI). Calculations were performed with Cell Quest analysis software (Becton-Dickinson, Heidelberg, Germany).

Bacterial killing

Bacterial killing was assessed as described previously [2]. A clinical isolate of a mucoid *P. aeruginosa* from a CF patient's sputum was subcultured overnight, grown to stationary phase, washed and pre-opsonized by incubation for 60 min at 37°C in 20% pooled fresh C5a-depleted human serum. After washing two times in PBS, the opsonized *P. aeruginosa* bacteria were resuspended in 1 ml of a mixture of HBSS supplemented with 0.1% gelatine (HBSS-gel) and tryptic soy broth (Difco Laboratories, Detroit, MI, USA). Neutrophils were then incubated at 37°C with bacteria (2×10^7 bacteria/ml) at a ratio of 5 bacteria per neutrophil. Where indicated, CXCL8 (100 nM) was added to the assay to stimulate CXCR1 function. At the times indicated aliquots of each mixture were removed and *P. aeruginosa* colonies were counted by serial dilution in distilled water and quantitative spread plating. Data are expressed as CFU/ml.

Respiratory burst

Neutrophils were incubated at equal numbers ($2 \times 10^6/\text{ml}$) with dihydrorhodamine-123 (DHR) stain for 20 min at 37°C . Formyl-methionyl-leucyl-phenylalanine (fMLP, 1 M) was then added to the cells for 30 min at 37°C . Where indicated, CXCL8 (100 nM) was added to the assay to stimulate CXCR1 function. The respiratory burst of the neutrophils was analyzed by measuring the rhodamine-123 fluorescence intensity using flow cytometry.

Statistical analysis

Derived genotype frequencies were compared with the expected allelic population equilibrium based on the Hardy-Weinberg equilibrium test (Pearson χ^2) to control for technical genotyping errors. Associations between SNPs and qualitative outcomes were first tested by using Pearson χ^2 [15] and Fisher's exact test, using a dominant model. Comparisons between quantitative outcomes in two patient groups were performed with the two-sided t test, while comparisons among more than two groups for quantitative outcomes were performed with analysis of variance. To test associations between SNPs and outcomes in complex models, logistic regression was used for qualitative outcomes, and linear regression for quantitative outcomes. Odds Ratios and 95%-confidence intervals are reported for dichotomous outcomes while the non-standardized regression coefficient B and the Betas are given for quantitative outcomes. Multivariate analysis was used to adjust for potentially confounding factors (age, sex, CFTR genotype, *P. aeruginosa*). Haplotype frequencies were estimated using the expectation-maximization algorithm [16]. To specify the effects of individual haplotypes we performed haplotype trend regressions in which the estimated probabilities of the haplotypes are modeled in a logistic regression as independent variables [17]. To account for multiple comparisons a Bonferroni adjustment was performed. A P value of <0.002 ($0.05 / 24$ tests) was considered to be statistically significant. Where indicated data are shown as means \pm standard error of the mean (SEM). Comparisons among all groups were

performed with ANOVA and comparisons between two patient groups were performed with the two-sided t test. Graphs were plotted with Prism 4.0 (Graph Pad Software, San Diego, CA, USA). Statistical analyses were performed with STATA version 8.2 for Windows (STATA Corporation, College Station, TX, USA) and PASW version 18.0 for Mac (SPSS Inc., Chicago, IL, USA).

RESULTS

Expression levels of CXCR1 and CXCR2 observed in peripheral blood neutrophils isolated from CF patients demonstrated two distinct expression populations at both the mRNA and protein level (Figure 1A). Based on a high variability in CXCR1 and CXCR2 mRNA and protein expression (Figure 1A and data not shown), we set out to assess whether genetic hot-spots within the CXCR1 and CXCR2 genes [11] associate with CXCR1/2 expression levels and CF lung disease severity in a well-characterized CF patient cohort (Table 1). One hundred ninety-one CF patients were $\Delta F508$ homozygous, 129 were $\Delta F508$ heterozygous carriers of the CFTR gene, and 122 had CFTR mutations other than $\Delta F508$. Two hundred forty-six patients were positive for *P. aeruginosa* microbiology (bacteria isolated in at least 2 consecutive sputum samples with a minimum of a six-month interval). Twenty-one single-nucleotide polymorphisms (SNPs) tagging the *CXCR1* and *CXCR2* loci were genotyped (Table 2). All polymorphisms had genotype distributions consistent with Hardy-Weinberg equilibrium ($P > 0.1$) and call rates ranged from 89.1 to 99.1%. The minor allele frequencies of *CXCR1/CXCR2* SNPs showed no significant difference in the CF population compared to an age-matched healthy control population (Supplementary Table 3). We found that four polymorphisms in *CXCR1* and three polymorphisms in *CXCR2* strongly correlated with age-adjusted lung function [9] in CF patients (Table 1). Patients with either haplotype *CXCR1*_Ha or haplotype *CXCR2*_Ha (heterozygous for the SNP cluster) displayed significantly lower age-adjusted longitudinal lung function (forced expiratory volume in 1 second, FEV₁) than CF patients homozygous for *CXCR1*_HA (FEV₁ \leq 70: OR = 4.90) or *CXCR2*_HA (FEV₁ \leq 70: OR = 3.80) (Table 2). Intriguingly, SNPs comprising both haplotypes *CXCR1*_Ha and *CXCR2*_Ha were in a remarkably high extent of linkage disequilibrium (Figure 1B). Consequently, an even higher risk for the development of lower lung function was found for the combined haplotype *CXCR1-2*_Ha when compared to homozygous carriers of *CXCR1-2*_HA (FEV₁ \leq 70: OR = 7.24) (Table 2). CF patients carrying the *CXCR1-2*_Ha haplotype

yielded significantly lower CXCR1 mRNA and protein levels combined with higher CXCR2 mRNA and protein levels in peripheral blood neutrophils when compared to *CXCR1-2_HA* CF individuals (Figure 1C). The genetic effect of the *CXCR1-2_Ha* haplotype on CXCR1 and CXCR2 mRNA or protein expression was not dependent on circulating serum levels of CXCR1/2 ligands, neutrophil apoptosis or activation status of neutrophils (data not shown).

To determine whether these genetic variants affected neutrophil effector functions, we analyzed CXCR1- and CXCR2-mediated antibacterial neutrophil functions in indexed CF patients carrying the *CXCR1-2_Ha* haplotype, in particular CXCR1-mediated respiratory burst and intracellular killing of *Pseudomonas aeruginosa* (*P. aeruginosa*) [2]. Indeed, neutrophils from patients carrying *CXCR1-2_Ha* featured decreased CXCR1-mediated antibacterial functionality (Figure 2).

DISCUSSION

Our results provide strong genetic and functional evidence for a clinically-relevant role of *CXCR1* and *CXCR2* haplotypes in modifying CF lung disease. Previous studies identified *CXCR1* as a key component in the maintenance and perpetuation of inflammation in CF lung disease [2]: *CXCR1* on neutrophils mediates bacterial killing, but is damaged in CF airways proteolytically, thereby favoring infections and sustaining auto-inflammation. These studies demonstrated that high *CXCR1* protein expression levels had a protective effect on lung function in CF patients. Inspired by these findings, we systematically analyzed associations of *CXCR1/CXCR2* SNPs and haplotypes with CF lung disease severity by means of a candidate gene association study. These genetic investigations identified a *CXCR1/CXCR2* haplotype cluster that had a significant impact on lung function and neutrophil functionality in CF patients.

Additional genetic modifiers for CF lung disease, including *TGFbeta1*, *IFRD1* and *MBL2* [4-7] have been previously described. Initially, the role of *TGFbeta1* as a CF modulator was suggested from studies with a case-control setting [6]. However, further studies have shown that designation of the risk allele for *TGFbeta1* varies between studies, most likely due to transmission ratio distortion and maternal confounder effects, and thus needs to be interpreted with caution [18]. A subsequent genome-wide scan was only able to identify *IFRD1* as a CF modifier. Interestingly, *IFRD1* polymorphisms were also significantly associated with variation in neutrophil effector function [7]. Initially, studies of *MBL2* as CF disease modifier gave inconsistent results [6, 19, 20]. However, a recent meta-analysis, taking the majority of available data sets into account, supports *MBL2* as major modifier of CF lung disease [21]. In a recent whole genome-wide approach, two significant loci on chromosomes 11p13 (*EHF-APIP* region) and 20q13.2 were identified that harbor genes of biologic relevance for CF [8]. Due to the distinct functionalities of *CXCR1*, *CXCR2*, *IFRD1* and *TGFbeta1* [22, 23] and as the candidate genes on chromosomes 11p13 and 20q13.2 remain

yet unidentified, the comparison of these potential CF lung disease modifiers at genetic, expression and functional levels was out of scope of this study. However, a mutual genetic influence on association results is unlikely given their different chromosomal locations (*CXCR1/2* Chr 2, *IFRD1* Chr 7, *TGFbeta1* Chr 19). Future studies are required to define their inter-relationship and contribution to CF lung disease.

Beyond the statistical association of the *CXCR1/CXCR2* haplotype cluster on longitudinal pulmonary function in our study, we found that CF individuals carrying the haplotype cluster showed disturbed antibacterial effector functionalities, in particular, CXCL8-induced respiratory burst-mediated generation of reactive oxygen species as well as CXCL8-induced killing of *P. aeruginosa*. These studies suggest that the described *CXCR1/CXCR2* haplotype cluster may modulate pulmonary outcome in CF patients through a dysregulation of neutrophilic innate effector functions.

The main limitation of this study is the number of CF patients included. Accordingly, as this study is the first report of a genetic association, these results have to be confirmed by independent investigators in other CF populations. Comparing the distribution of FEV1 values across allelic groups confirmed the strong association of four polymorphisms in *CXCR1* and three polymorphisms in *CXCR2* with age-adjusted lung function (Table 1). Interestingly, we observed that the minor allele frequencies (MAFs) of the majority of *CXCR2* SNPs were higher compared to *CXCR1* SNPs (Table 1). Similar MAF distributions of *CXCR1* and *CXCR2* SNPs have been demonstrated previously in a control cohort by Vasilescu *et al.* [11]. Neither the frequency of $\Delta F508$ homozygous, $\Delta F508$ heterozygous, or non- $\Delta F508$ CF patients differed significantly between HA and Ha carriers. Linear regression analysis showed that *CFTR* genotypes had no confounding effects on the *CXCR1/2* haplotype observed.

Taken together, we have identified a *CXCR1/2* haplotype cluster that is associated with lung function in CF patients, and synergistically affects mRNA and protein expression, thereby modulating neutrophil effector functions. As both CXCR1 and CXCR2 are G protein

coupled receptors, our results may provide new pharmacological approaches for the treatment of CF lung disease.

AUTHOR CONTRIBUTIONS

Kormann, Hector and Hartl designed the experiments.

Kormann, Hector, Illig, Klopp, Zeilinger, Marcos, Kappler, Mays, Carevic, Moepps, Rieber, Eickmeier, Zielen, Gaggar and Griesse generated reagents and performed the experiments.

Kormann and Hartl wrote and edited the manuscript.

FIGURE LEGENDS

Figure 1. CXCR1/CXCR2 expression profiles and *CXCR1/CXCR2* haplotypes in CF patients


A. CXCR1 and CXCR2 mRNA expression levels were quantified in peripheral blood neutrophils from CF patients by real-time RT-PCR (left panel). CXCR1 and CXCR2 protein surface expression levels on CF neutrophils were quantified by FACS (right panel). MFI: mean fluorescence intensity.

B. Location and linkage disequilibrium (R^2 and D') of *CXCR1* and *CXCR2* polymorphisms genotyped in the CF population. In this plot, each square represents a pairwise comparison between two SNPs and the respective R^2 is given within each square. Darker square colors of red indicate higher values of D' , up to a maximum of 1. SNPs are numbered sequentially, 5' to 3', and their relative location is indicated along the top.


C. CXCR1 and CXCR2 mRNA (upper panel) and protein surface (lower panel) expression levels in CF patients stratified for HA or Ha haplotype. MFI: mean fluorescence intensity.

* $P < 0.01$

A



B



C





Figure 2. *CXCR1/CXCR2* haplotypes modulate antibacterial neutrophil functions in CF patients

(A,B) Neutrophils were isolated from CF patients with the HA (n=3) or Ha (n=3) haplotype and CXCR1- and CXCR2-mediated neutrophil effector functions were analyzed as described previously [2]. * $P < 0.01$

A. CXCR1 mediated respiratory burst measured by FACS (DHR: dihydrorhodamine). After staining with dihydrorhodamine-1,2,3 (DHR) for 20 min at 37°C, cells were stimulated with fMLP (1 M) for an additional 30 min in the presence of CXCL8 (100 nM), and the respiratory burst was analyzed by flow cytometry. Results are depicted as the mean fluorescence intensity (MFI) of the total neutrophil population.

B. CXCR1 mediated killing of *P. aeruginosa*. Isolated neutrophils were incubated with pre opsonized *P. aeruginosa* bacteria at a ratio of 5 bacteria per cell for 150 min in the presence of CXCL8 (100 nM).



TABLES

Table 1. *CXCR1* and *CXCR2* tagging SNPs and their association with lung function.

CXCR1

SNP	Position	Location/ Function	Alleles	MAF FEV ₁ %@20yrs≤70	MAF FEV ₁ %@20yrs>70	OR	<i>P</i> value
rs2671222	-2668	Promoter	G/A	0.046	0.065	0.66	0.411
rs17838611	-2423	Promoter	G/A	0.027	0.007	3.92	0.028
rs16858841	-2329	Promoter	C/T	0.077	0.015	6.02	1.58 x 10 ⁻⁵
rs3138060	-1566	Intron	C/G	0.044	0.066	0.63	0.167
rs16858816	-143	Intron	C/T	0.066	0.016	4.61	2.31 x 10 ⁻⁴
rs16858811	92	Met/Arg	G/T	0.066	0.014	5.29	1.41 x 10 ⁻⁴
rs16858808	1003	Arg/Cys	C/T	0.052	0.016	3.55	0.003

CXCR2

SNP	Position	Location/ Function	Alleles	MAF FEV ₁ %@20yrs≤70	MAF FEV ₁ %@20yrs>70	OR	<i>P</i> value
rs3890158	-9203	Promoter	A/G	0.468	0.466	1.01	0.948
rs45493792	-9191	Promoter	-/T	0.364	0.370	0.94	0.791
rs3890157	-9185	Promoter	T/G	0.077	0.025	3.47	4.73 x 10 ⁻⁴
rs35231134	-9179	Promoter	-/T	0.510	0.498	1.05	0.822
rs4674258	-8909	Promoter	C/T	0.343	0.370	0.77	0.247
rs4674259	-8490	5'-UTR	A/G	0.382	0.354	1.34	0.741
rs17844697	-270	Intron	G/A	0.423	0.445	0.99	0.953
rs11574750	768	Val/Val	C/T	0.077	0.023	3.75	2.77 x 10 ⁻⁴
rs2230054	786	Leu/Leu	C/T	0.323	0.338	0.88	0.572
rs45606837	936	Leu/Leu	C/T	0.023	0.009	2.67	0.098
rs1126579	1209	3'-UTR	C/T	0.383	0.354	1.34	0.212
rs13306441	1420	3'-UTR	A/G	0.070	0.017	4.48	1.64 x 10 ⁻⁴
rs17844765	1437	3'-UTR	C/T	0.007	0.006	1.20	0.844
rs1126580	1441	3'-UTR	C/T	0.433	0.447	0.99	0.955

MAF, minor allele frequency; FEV₁%@20yrs, age-adjusted (20 years) longitudinal forced expiratory volume (FEV₁) [9]; OR, odds ratio (in bold if significant after Bonferroni correction).

Table 2. *CXCR1* and *CXCR2* risk allele haplotype combinations and their association with lung function.

	Polymorphism position							MAF FEV ₁ %@20yrs		OR	P value
	<i>CXCR1</i>				<i>CXCR2</i>			≤70	>70		
	-2329	-143	92	1003	-9185	768	1420				
<i>CXCR1</i> _Ha	T	T	G	T	-	-	-	0.063	0.014	4.90	2.17 x 10 ⁻⁴
<i>CXCR2</i> _Ha	-	-	-	-	G	T	G	0.059	0.017	3.80	0.001
<i>CXCR1-2</i> _Ha	T	T	G	T	G	T	G	0.063	0.010	7.24	2.30 x 10 ⁻⁵

MAF, minor allele frequency; FEV₁%@20yrs, age-adjusted (20 years) longitudinal forced expiratory volume (FEV₁) [9]; OR, odds ratio; *CXCR1*_Ha and *CXCR2*_Ha combine all risk alleles of *CXCR1* or *CXCR2*, respectively; *CXCR1-2*_Ha combines risk alleles of both *CXCR1* and *CXCR2*.

REFERENCES

1. Chmiel JF, Berger M, Konstan MW. The role of inflammation in the pathophysiology of CF lung disease. *Clin Rev Allergy Immunol* 2002; 23: 5-27.
2. Hartl D, Latzin P, Hordijk P, Marcos V, Rudolph C, Woischnik M, Krauss-Etschmann S, Koller B, Reinhardt D, Roscher AA, Roos D, Griesse M. Cleavage of CXCR1 on neutrophils disables bacterial killing in cystic fibrosis lung disease. *Nat Med* 2007; 13: 1423-1430.
3. Knowles MR. Gene modifiers of lung disease. *Curr Opin Pulm Med* 2006; 12: 416-421.
4. Wojnarowski C, Frischer T, Hofbauer E, Grabner C, Mosgoeller W, Eichler I, Ziesche R. Cytokine expression in bronchial biopsies of cystic fibrosis patients with and without acute exacerbation. *The European respiratory journal* 1999; 14: 1136-1144.
5. Garred P, Pressler T, Madsen HO, Frederiksen B, Svejgaard A, Hoiby N, Schwartz M, Koch C. Association of mannose-binding lectin gene heterogeneity with severity of lung disease and survival in cystic fibrosis. *The Journal of clinical investigation* 1999; 104: 431-437.
6. Drumm ML, Konstan MW, Schluchter MD, Handler A, Pace R, Zou F, Zariwala M, Fargo D, Xu A, Dunn JM, Darrah RJ, Dorfman R, Sandford AJ, Corey M, Zielenski J, Durie P, Goddard K, Yankaskas JR, Wright FA, Knowles MR. Genetic modifiers of lung disease in cystic fibrosis. *The New England journal of medicine* 2005; 353: 1443-1453.
7. Gu Y, Harley IT, Henderson LB, Aronow BJ, Vietor I, Huber LA, Harley JB, Kilpatrick JR, Langefeld CD, Williams AH, Jegga AG, Chen J, Wills-Karp M, Arshad SH, Ewart SL, Thio CL, Flick LM, Filippi MD, Grimes HL, Drumm ML, Cutting GR, Knowles MR, Karp CL. Identification of IFRD1 as a modifier gene for cystic fibrosis lung disease. *Nature* 2009; 458: 1039-1042.
8. Wright FA, Strug LJ, Doshi VK, Commander CW, Blackman SM, Sun L, Berthiaume Y, Cutler D, Cojocar A, Collaco JM, Corey M, Dorfman R, Goddard K, Green D, Kent JW, Jr., Lange EM, Lee S, Li W, Luo J, Mayhew GM, Naughton KM, Pace RG, Pare P, Rommens JM, Sandford A, Stonebraker JR, Sun W, Taylor C, Vanscoy LL, Zou F, Blangero J, Zielenski J, O'Neal WK, Drumm ML, Durie PR, Knowles MR, Cutting GR. Genome-wide association and linkage identify modifier loci of lung disease severity in cystic fibrosis at 11p13 and 20q13.2. *Nature genetics* 2011; 43: 539-546.
9. Schluchter MD, Konstan MW, Drumm ML, Yankaskas JR, Knowles MR. Classifying severity of cystic fibrosis lung disease using longitudinal pulmonary function data. *Am J Respir Crit Care Med* 2006; 174: 780-786.
10. Holle R, Happich M, Lowel H, Wichmann HE. KORA--a research platform for population based health research. *Gesundheitswesen* 2005; 67 Suppl 1: S19-25.
11. Vasilescu A, Terashima Y, Enomoto M, Heath S, Poonpiriya V, Gatanaga H, Do H, Diop G, Hirtzig T, Auewarakul P, Lauhakirti D, Sura T, Charneau P, Marullo S, Therwath A, Oka S, Kanegasaki S, Lathrop M, Matsushima K, Zagury JF, Matsuda F. A haplotype of the human CXCR1 gene protective against rapid disease progression in HIV-1+ patients. *Proc Natl Acad Sci U S A* 2007; 104: 3354-3359.
12. Kormann MS, Carr D, Klopp N, Illig T, Leupold W, Fritzsche C, Weiland SK, von Mutius E, Kabesch M. G-Protein-coupled receptor polymorphisms are associated with asthma in a large German population. *Am J Respir Crit Care Med* 2005; 171: 1358-1362.
13. Koller B, Kappler M, Latzin P, Gaggari A, Schreiner M, Takyar S, Kormann M, Kabesch M, Roos D, Griesse M, Hartl D. TLR expression on neutrophils at the pulmonary site of infection: TLR1/TLR2-mediated up-regulation of TLR5 expression in cystic fibrosis lung disease. *Journal of immunology* 2008; 181: 2753-2763.

14. Hartl D, Krauss-Etschmann S, Koller B, Hordijk PL, Kuijpers TW, Hoffmann F, Hector A, Eber E, Marcos V, Bittmann I, Eickelberg O, Griesse M, Roos D. Infiltrated neutrophils acquire novel chemokine receptor expression and chemokine responsiveness in chronic inflammatory lung diseases. *Journal of immunology* 2008; 181: 8053-8067.
15. Sasieni PD. From genotypes to genes: doubling the sample size. *Biometrics* 1997; 53: 1253-1261.
16. Excoffier L, Slatkin M. Maximum-likelihood estimation of molecular haplotype frequencies in a diploid population. *Mol Biol Evol* 1995; 12: 921-927.
17. Zaykin DV, Westfall PH, Young SS, Karnoub MA, Wagner MJ, Ehm MG. Testing association of statistically inferred haplotypes with discrete and continuous traits in samples of unrelated individuals. *Hum Hered* 2002; 53: 79-91.
18. Becker T, Jansen S, Tamm S, Wienker TF, Tummler B, Stanke F. Transmission ratio distortion and maternal effects confound the analysis of modulators of cystic fibrosis disease severity on 19q13. *Eur J Hum Genet* 2007; 15: 774-778.
19. Gabolde M, Guillaud-Bataille M, Feingold J, Besmond C. Association of variant alleles of mannose binding lectin with severity of pulmonary disease in cystic fibrosis: cohort study. *Bmj* 1999; 319: 1166-1167.
20. Yarden J, Radojkovic D, De Boeck K, Macek M, Jr., Zemkova D, Vavrova V, Vlietinck R, Cassiman JJ, Cuppens H. Polymorphisms in the mannose binding lectin gene affect the cystic fibrosis pulmonary phenotype. *J Med Genet* 2004; 41: 629-633.
21. Chalmers JD, Fleming GB, Hill AT, Kilpatrick DC. Impact of mannose-binding lectin insufficiency on the course of cystic fibrosis: A review and meta-analysis. *Glycobiology* 2011; 21: 271-282.
22. Moore B, Murphy RF, Agrawal DK. Interaction of tgf-beta with immune cells in airway disease. *Curr Mol Med* 2008; 8: 427-436.
23. Vietor I, Huber LA. Role of TIS7 family of transcriptional regulators in differentiation and regeneration. *Differentiation* 2007; 75: 891-897.